You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 286 No. 1, July 4, 2001 TABLE OF CONTENTS
  JAMA
  •  Online Features
  From the Centers for Disease Control and Prevention: Morbidity and Mortality Weekly Report
 This Article
 •Extract
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA

Shortage of Spectinomycin

JAMA. 2001;286:40.

MMWR. 2001;50:470

In April 2001, Pharmacia Corporation (Peapack, New Jersey) announced it was discontinuing U.S. production of spectinomycin (Trobicin®)* because of low sales volume; remaining spectinomycin inventory will expire on June 30, 2001. No other pharmaceutical company manufactures or sells spectinomycin in the United States.

CDC recommends treating patients infected with Neisseria gonorrhoeae who have contraindications to cephalosporins and fluoroquinolones with spectinomycin.1 Patients in this category include: (1) pregnant women with documented cephalosporin allergies (fluoroquinolones are contraindicated in pregnancy); and (2) patients with documented cephalosporin allergies who acquired gonorrhea infection in areas where fluoroquinolone-resistant N. gonorrhoeae is endemic (e.g., Asia, Hawaii, and other Pacific Islands).2

For access to spectinomycin until June 30, contact Wendy Johnson, Pharmacia Corporation, telephone (800) 976-7741, ext. 30110 or fax (800) 852-6421. In response to this shortage, CDC and the Food and Drug Administration are working with Pharmacia Corporation to identify a solution. Interim alternative treatment recommendations are available at http://www.cdc.gov/std/specshortage.htm or from CDC's Fax Information System (888) 232-3299 ([888] CDC-FAXX), by entering document number 210100.


*Use of trade names is for identification only and does not imply endorsement by CDC or the U.S. Department of Health and Human Services.


REFERENCES

1. CDC. 1998 Guidelines for treatment of sexually transmitted diseases. MMWR. 1998;47(no. RR-1).
2. CDC. Fluoroquinolone-resistance in Neisseria gonorrhoeae, Hawaii, 1999, and decreased susceptibility to azithromycin in N. gonorrhoeae, Missouri, 1999. MMWR Morb Mortal Wkly Rep. 2000;49:833-7. PUBMED


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

U.S. Centers for Disease Control and Prevention Guidelines for the Treatment of Sexually Transmitted Diseases: An Opportunity To Unify Clinical and Public Health Practice
Workowski et al.
ANN INTERN MED 2002;137:255-262.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2001 American Medical Association. All Rights Reserved.